Orphan drugs—or orphan diseases?

  • W. H. Lyle
Chapter

Abstract

In the beginning, the question was that of how to provide drugs for rare diseases; and the beginning in this country was perhaps around 1972 when the ‘Pharmaceutical Working Party’ of the National Economic Development Office discussed the matter and agreed to keep it under review [1]. I was permitted to raise the issue more publicly at a symposium under the chairmanship of the late Sir Derrick Dunlop in 1973 [2], while also in the USA the Intra-agency Committee on Drugs of Limited Commercial Value was established in 1973, under the direction of the Food and Drug Administration (FDA), to ascertain such needs and where the obstacles lay to their being met. Nothing came of this and the committee was disbanded 2 years later.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Reference

  1. [1]
    National Economic Development Office 1972. Focus on pharmaceuticals. Her Majesty’s Stationery Office, London.Google Scholar
  2. [2]
    Lyle, W. H. Drugs for rare diseases. Postgrad Med J 1974; 50: 107–8.CrossRefGoogle Scholar
  3. [3]
    Anon. Drugs for rare diseases: whose responsibility? Lancet 1974; 1: 440.Google Scholar
  4. [4]
    Hurley, R. Round table discussion. In: Scheinberg, I. H., Walshe, J. M., eds. Orphan Diseases and Orphan Drugs, London. Manchester University Press, 1986; 204.Google Scholar
  5. [5]
    Provost, G. P. Homeless or orphan drugs. Am J Hosp Pharm 1968; 25: 609–11.Google Scholar
  6. [6]
    Spilker, B. Development of orphan drugs. Trends Pharm. Sci. 1985; 6: 185–8.CrossRefGoogle Scholar
  7. [7]
    Cumings, J. N. The effects of BAL in hepatolenticular degeneration. Brain 1951; 74: 10–22.CrossRefGoogle Scholar
  8. [8]
    Walshe, J. M. Penicillamine: a new oral therapy for Wilson’s disease. Am J Med 1956; 2: 487–95.CrossRefGoogle Scholar
  9. [9]
    Scheinberg, I. H. Summing up. In: Lyle, W. H, Kleinman R. eds. Penicillamine at 21: its place in therapeutics now. Proc Roy Soc Med 177; 70: Suppl. 3, 23.Google Scholar
  10. [10]
    Walshe, J. M. The story of triethylene tetramine dihydrochloride, a new chelating agent for copper. In: Karch, F. E. ed. Orphan Drugs, New York: Marcel Dekker Inc, 1982; 57–71.Google Scholar
  11. [11]
    Lewis, R. Doctor accuses three firms of lack of life-saving drugs. Chicago Sun Times 1960. 16 April, 1.Google Scholar
  12. [12]
    Anon. Drugs for rare diseases, (editorial). Lancet 1976; 2: 835–6.Google Scholar
  13. [13]
    Humphreys, R., Purchase, R. The development of trientine hydrochloride 1977–85. In: Scheinberg, I. H., Walshe, J. M., eds. Orphan Diseases and Orphan Drugs, London: Manchester University Press, 1986; 53–5.Google Scholar
  14. [14]
    Bachrach, W. H. FDA evaluation of an orphan drug. In: Scheinberg, I. H., Walshe, J. M., eds. Orphan Diseases and Orphan Drugs, London: Manchester University Press, 1986; 190–4.Google Scholar
  15. [15]
    Mann, R. D. UK regulatory requirements for orphan drugs. In: Scheinberg, I. H., Walshe, J. M., eds. Orphan Diseases and Orphan Drugs, London. Manchester University Press, 1986; 146–9.Google Scholar
  16. [16]
    Van Woert, M. H. Profitable and non-profitable drugs. New Eng J Med 1978; 298: 903–6.CrossRefGoogle Scholar
  17. [17]
    Waxman, H. A. The history and development of the Orphan Drug Act. In: Scheinberg, I. H., Walshe, J. M., eds. Orphan Diseases and Orphan Drugs, London: Manchester University Press, 1986; 135–45.Google Scholar
  18. [18]
    Lock, S. Self-help groups: the fourth estate in medicine? Br Med J 1986; 293: 1596–1600.CrossRefGoogle Scholar
  19. [19]
    Bachrach, W. G., Binns, T. B., Buckler, J. et al. Round table discussion. In: Scheinberg, I. H., Walshe, J. M., eds. Orphan Diseases and Orphan Drugs, London: Manchester University Press, 1986; 204–15.Google Scholar
  20. [20]
    Van Woert, M. H., Chung, E., eds. Cooperative Approaches to Research and Development of Orphan Drugs, New York: A. R. Liss Inc. 1985: 1–204.Google Scholar
  21. [21]
    Levy, R. Tetrahydroaminoacridine and Alzheimer’s disease. Lancet 1987; 1: 322.CrossRefGoogle Scholar
  22. [22]
    Forbes, S. Finding a home for orphan drugs. Fed Proc (public affairs) 1986; 45: 5a–8a.Google Scholar
  23. [23]
    Brewer, G. J., ed. Orphan Drugs and Orphan Diseases, New York: A. R. Liss Inc. 1983; 1–2.Google Scholar
  24. [24]
    Anon. Something more than a clinical research centre, (editorial). Lancet 1987; 1: 1137.Google Scholar
  25. [25]
    Burley, D. M. The decline and fall of thalidomide. In: Scheinberg, I. H., Walshe, J. M., eds. Orphan Diseases and Orphan Drugs, London: Manchester University Press, 1986; 195–201.Google Scholar

Copyright information

© The International Federation of Associations of Pharmaceutical Physicians 1988

Authors and Affiliations

  • W. H. Lyle

There are no affiliations available

Personalised recommendations